24th Aug 2005 12:00
24 August 2005Shire Pharmaceuticals Group plc (the "Company")The Company announces that it was notified on 23 August 2005 under Sections 198to 203 of the Companies Act that, at close of business on 19 August 2005, TheGoldman Sachs Group, Inc., was interested in 23,691,744 ordinary shares of ‚£0.05p each in the capital of the Company. This holding represents 4.799 percent of the issued ordinary share capital of the Company.V HemmingDeputy Company SecretaryFor further information please contact:Investor Relations Clƒ©a Rosenfeld (Rest of the World) +44 1256 894 160 Brian Piper (North America) +1 484 595 8252 Notes to editorsShire Pharmaceuticals Group plcShire Pharmaceuticals Group plc (Shire) is a global specialty pharmaceuticalcompany with a strategic focus on meeting the needs of the specialist physicianand currently focuses on developing and marketing products in the areas ofcentral nervous system (CNS), gastrointestinal (GI), renal diseases and humangenetics. Shire has operations in the world's key pharmaceutical markets (US,Canada, UK, France, Italy, Spain and Germany) as well as a specialist drugdelivery unit in the US.For further information on Shire, please visit the Company's website: www.shire.com.Hampshire International Business Park Chineham Basingstoke Hampshire RG24 8EP United Kingdom Tel +44 (0)1256 894000 Fax +44 (0)1256 894708 www.shire.com Press Release Registered in England 2883758 Registered Office as aboveENDShire Pharmaceuticals Group PLCRelated Shares:
Shire